Safinamide Disease Interactions
There are 5 disease interactions with safinamide.
Dopamine agonists (applies to safinamide) hypotension
Major Potential Hazard, Moderate plausibility.
Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.
References
- Hoehn MM (1975) "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol, 32, p. 50-1
- Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y (1990) "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol, 30, p. 194-9
- (2001) "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn
- (2001) "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals
- (2001) "Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals
- (2001) "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim
- (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
- (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals
- (2006) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA
- (2007) "Product Information. Neupro (rotigotine)." Schwarz Pharma
- (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
Dopaminergic antiparkinson agents (applies to safinamide) psychosis
Major Potential Hazard, Moderate plausibility.
Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.
References
- (2001) "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn
- (2001) "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim
- (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
- (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals
- (2001) "Product Information. Lodosyn (carbidopa)." DuPont Pharma
- (2006) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA
- (2007) "Product Information. Neupro (rotigotine)." Schwarz Pharma
- (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
Safinamide (applies to safinamide) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Safinamide is contraindicated in patients with severe hepatic dysfunction (Child-Pugh C). In patients with moderate hepatic impairment the maximum recommended dose is 50 mg orally once a day. If a patient taking this dose progresses from moderate to severe hepatic impairment, safinamide should be discontinued.
References
- (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
Safinamide (applies to safinamide) hypertension
Moderate Potential Hazard, Moderate plausibility.
Safinamide may cause hypertension or exacerbate existing hypertension. Patients should be monitored for new onset hypertension or hypertension that is not adequately controlled after starting treatment. Dosage adjustment may be necessary if elevation of blood pressure is sustained.
References
- (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
Safinamide (applies to safinamide) retinal pathology
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Retinal Disorder, Uveitis
Animal studies with safinamide showed retinal degeneration, loss of photoreceptor cells, cataracts, and retinal scarring. Patients should be periodically monitored for visual changes, especially if they have a history of retinal/macular degeneration, uveitis, inherited retinal conditions, family history of retinal disease, albinism, retinitis pigmentosa, or active retinopathy (e.g., diabetic retinopathy).
References
- (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
Safinamide drug interactions
There are 484 drug interactions with safinamide.
Safinamide alcohol/food interactions
There are 3 alcohol/food interactions with safinamide.
More about safinamide
- safinamide consumer information
- Check interactions
- Compare alternatives
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- Drug class: dopaminergic antiparkinsonism agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.